SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9989)

VOLUNTARY ANNOUNCEMENT
FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF AR-301 IN GREATER CHINA

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "**Company**", together with its subsidiaries referred to as the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that our controlled subsidiary, Shenzhen Arimab Biomedical Co., Ltd., has dosed the first patient in the phase III clinical trial of AR-301 (fully human monoclonal antibody Drugs of the Group) of adjunctive therapy to antibiotics in the treatment of ventilator-associated pneumonia caused by S. aureus (the "**AR-301-002**") in Greater China on June 23, 2021. This pivotal trial in Greater China is expected to enroll 30 patients from a total of 26 clinical sites.

The Phase III clinical trial, namely AR-301-002, is a random, double-blind, placebo-controlled, multicenter clinical study to evaluate the efficacy and safety of AR-301-002 as an adjunctive therapy with antibiotics in patients diagnosed with ventilator associated pneumonia (VAP) caused by S. aureus. The major clinical effectiveness goal of this study is to evaluate the difference of clinical cure rates between SOC therapy alone and adjunctive therapy with SOC and AR-301-002 on the 21st day. The Company has defined a rigid clinical cure standard together with clinical experts in the field.

DETAILS OF AR-301-002

AR-301-002 is a fully human monoclonal IgG1 antibody (mAb) that specifically targets S. aureus alpha-toxin. It is being developed by the Company's joint-stock subsidiary Aridis Pharmaceuticals, Inc. (a company listed on the NASDAQ, stock code: ARDS). It is combined with the standard therapy of antibiotics for treating patients diagnosed with ventilator associated pneumonia (VAP) caused by S. aureus. Results of a phase I/II trial completed in the United States in the earlier stage have shown that patients treated with AR-301-002 consistently demonstrated less time spent under

mechanical ventilation and higher rates of S. aureus eradication as compared to those treated with antibiotics alone. AR-301-002 was granted fast track designation by the FDA and orphan drug designation by the EMA.

Announcement is hereby given.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
June 23, 2021

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.